Abstract
Background Symptom recognition is necessary to identify people with possible Covid-19. Clinical case definitions vary in type and number of symptoms included. No large studies have investigated how these perform for hospitalized patients of different ages and sex.
Methods We used international prospective observational data from patients admitted to hospital with laboratory-confirmed Covid-19. We investigated how symptoms varied by age and sex. We performed logistic regression to assess the relationship of age and sex with the most prevalent symptoms in our dataset and with published case definitions, allowing for clustering by country as a random intercept.
Results 60 161 patients from 43 countries were included, with median age 70 years (interquartile range 55– 82). Fever (68%), cough (68%) and shortness of breath (63%) were the most prevalent symptoms. Their prevalence was greater among patients aged 30–60 years (respectively 79%, 78%, 66%), and lower in children (≤18 years: 68%, 47%, 22%) and older adults (≥70 years: 61%, 62%, 61%). The most sensitive case definition assessed was one or more of cough, shortness of breath, fever, muscle pains or sore throat, met by 92% of the whole cohort. Confusion was the most prevalent symptom for patients whose symptoms did not meet any of the assessed case definitions. Regression models showed significant differences in symptoms with age, and considerable heterogeneity between countries.
Conclusions Older adults and children admitted to hospital with Covid-19 are less likely to present with typical symptoms of cough, fever and shortness of breath. Vigilance for atypical symptoms towards extremities of age increases sensitivity of identifying Covid-19.
Summary Typical symptoms of fever, cough and shortness of breath are less common in people admitted to hospital with Covid-19 toward extremities of age. Published case definitions appear less sensitive toward extremes of age, and atypical symptoms need to be recognised.
- Covid-19
- SARS-CoV-2
- symptoms
- diagnosis
- case definition
Competing Interest Statement
M. Cheng declares grants from McGill Interdisciplinary Initiative in Infection and Immunity, and Canadian Institutes of Health Research; and personal fees from GEn1E Lifesciences (as a member of the scientific advisory board) and nplex biosciences (as a member of the scientific advisory board); M. Cummings and M. O'Donnell participated as investigators for completed and ongoing clinical trials evaluating the efficacy and safety of remdesivir (sponsored by Gilead Sciences) and convalescent plasma (sponsored by Amazon), in hospitalized patients with Covid-19 - support for this work is paid to Columbia University; J. C. Holter declared grants from Research Council of Norway [grant 312780], and Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, during the conduct of the study; A. Kimmoun declared personal fees (payment for lectures) from Baxter, Aguettant, Aspen; D. Kumar declared grants and personal fees from Roche, GSK and Merck, and personal fees from Pfizer and Sanofi; F.X. Lescure declared personal fees (payment for lectures) from Gilead, MSD; and travel/accommodation/meeting expenses from Astellas, Eumedica, MSD;bA. Pesenti declared personal fees from Maquet, Novalung/Xenios, Baxter, and Boehringer Ingelheim; R.Tedder reports grants from MRC/UKRI during the conduct of the study, and has a patent United Kingdom Patent Application No. 2014047.1 "SARS-CoV-2 antibody detection assay" issued; J. Troost declared personal fees from General Electric and Procter and Gamble.
Funding Statement
This work was supported by the Department for International Development and Wellcome Trust [215091/Z/18/Z]; the Bill and Melinda Gates Foundation [OPP1209135]. Country-specific support was provided by the Canadian Institutes of Health Research Coronavirus Rapid Research Funding Opportunity [OV2170359]; the Health Research Board Ireland [CTN Award 2014-012]; National Institute for Health Research (NIHR) [award CO-CIN-01]; the Medical Research Council (MRC) [grant MC_PC_19059]; the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [award 200907]; NIHR HPRU in Respiratory Infections at Imperial College London with PHE [award 200927]; Liverpool Experimental Cancer Medicine Centre [grant reference C18616/A25153]; NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013]; EU Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) [FP7 project 602525]; National Institutes of Health (NIH) [UL1TR002240]; and NIHR Clinical Research Network infrastructure support. We acknowledge the generous support of all ISARIC Partners who have contributed data and expertise to this analysis, with or without dedicated funding. The views expressed are those of the authors and not necessarily those of the funders or institutions listed above.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the World Health Organization Ethics Review Committee (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site according to local requirements.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We welcome applications for UK data through the ISARIC 4C Independent Data and Material Access Committee (https://isaric4c.net). Requests for access to non-UK data can be sent to covid19{at}iddo.org.
